Mireca Medicines GmbH

Mireca Medicines GmbH

Mireca Medicines GmbH (Mireca) is a Tübingen based pre-clinical stage bio-pharmaceutical company focusing on research and development of treatments for rare, neuro-degenerative eye diseases. Mireca Medicines GmbH (Mireca) ist ein präklinisches, bio-pharmazeutisches Unternehmen mit Sitz in Tübingen welches sich auf die Forschung und Entwicklung von Behandlungen für seltene, neuro-degenerative Augenerkrankungen fokussiert.

Mireca Medicines GmbH (Mireca) is a Tübingen based pre-clinical stage bio-pharmaceutical company focusing on research and development of treatments for rare, neuro-degenerative eye diseases. Mireca was set up with the aim to translate research data generated in the EU-funded DRUGSFORD project (www.drugsford.eu) into treatments for patients, with all original consortium partners as shareholders. Thus providing access to a network of experienced scientists and entrepreneurs, all relevant intellectual property and a GMP-compliant manufacturing process. The lead compound LP-DF003 is a small molecule capable of down regulating over expressed cGMP in inherited retina degeneration, covering a broad amount of underlying gene mutations. Mireca will first develop LP-DF003 for Retinitis Pigmentosa for which the EMA Orphan Drug Status (ODD) was granted and no other treatment option is currently available.

Category

Biotechnology

Activity Development, Health, Life Science, Pharmacy, Therapy

Management

CEO: Barbara Brunnhuber, Ir MSc
CSO: Prof. Dr. François Paquet-Durand

Year of foundation

2017

Employees

3

Supervisory board

Chairman: Dr. Pieter Gaillard
Members: Dr. Hans-Gottfried Genieser, Dr. Janet Hoogstraate, MBA